Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin for Prevention of Post Stroke Delirium
NCT04122599Phase 3Unknown
- Sponsor
- University Hospital Tübingen
- Start
- Jul 2017
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of melatonin in delirium, sponsored by University Hospital Tübingen. Primary endpoint: Change of delir prevalence at 3 months. Status: unknown.
02
Drugs
melatonin
03
Conditions
delirium
Beyond the preview
Go deeper on NCT04122599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122599.